Indivior Pharmaceuticals, Inc. (INDV) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Indivior Pharmaceuticals, Inc. (INDV) closed at USD 34.16 on 2026-10-14, a change of +37.1 % over the past year, with a market capitalization of USD 3.97B.

Indivior Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Indivior Pharmaceuticals, Inc. key figures

Previous close

USD 34.16 (2026-10-14)

1-year change

+37.1 %

Market cap

USD 3.97B

Enterprise value

USD 4.25B

P/E ratio (trailing)

12.05

P/E ratio (forward)

6.89

EPS (trailing)

2.79

EPS (forward)

4.88

PEG ratio

n/a

Price to book

-19.07

Revenue growth

13.6 %

Earnings growth

600 %

Dividend per share (trailing)

0.00

Short ratio

5.23

Employees

827

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Indivior Pharmaceuticals, Inc. and compare it with other stocks.